The efficacy of febuxostat or topiroxostat on nephropathy in type 2 diabetes with hyperuricemia: A randomized clinical trial

The efficacy of febuxostat or topiroxostat on nephropathy in type 2 diabetes with hyperuricemia: A randomized clinical trial - The efficacy of febuxostat or topiroxostat on diabitic nephropathy: A randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031708

Enrollment

120

Registered

2018-03-15

Start date

2018-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes with hyperuricemia

Interventions

Febxostat 10mg/day for 24 weeks Topiroxostat 40mg/day for 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients diagnosed with type 2 diabetes, who has diabetic nephropaty. 2)Patients diagnosed hyperuricemia. 3)Aged over 20. 4)Having provided voluntary written consent for participation in this study.

Exclusion criteria

Exclusion criteria: 1)Patients whose baseline eGFR were <30 ml/min/1.73m^2. 2)Patients treated with uric acid synthesis inhibitors or uricosuric drugs. 3)Patients with severe infections. 4)Patients who are receiving chemotherapy with malignancy. 6)Patients who are judged by an investigator to be inappropriate for this study for any other reason.

Design outcomes

Primary

Measure	Time frame
The improvement in urinary alubumin creatinine ratio after 24 weeks of treatment.	—

Countries

Japan

Contacts

Public ContactTomoko Okuyama

Yokohama City University Hospital Department of Endocrinology and Metabolism

oku_tomo@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026